in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The therapy met the co-primary endpoint of the WAYPOINT ...

(IN BRIEF) A Phase III trial of Tezspire (tezepelumab) by AstraZeneca and Amgen has shown significant benefits for patients ...

November 08, 2024--(BUSINESS WIRE)--Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP ... significant and clinically ...

AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc (NASDAQ:AMGN) released topline data from the Phase 3 WAYPOINT trial of Tezspire ...

A phase 3 study has shown that when compared with placebo, Tezspire provided a statistically significant and clinically ...

Amgen (AMGN) and AstraZeneca's (AZN) asthma therapy Tezspire hits main goals in the Phase 3 trial for chronic rhinosinusitis ...

Results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps showed that AstraZeneca (AZN) and ...

Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with ...

(Alliance News) - AstraZeneca PLC on Friday said it received positive results from a trial of Tezspire as a treatment for chronic rhinosinusitis with nasal polyps.

compared to a placebo in adults with severe chronic rhinosinusitis with nasal polyps, showed a "statistically significant and ...

Am­gen and As­traZeneca said on Fri­day that their asth­ma drug Tezspire re­duced nasal con­ges­tion and the size of nasal ...